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July 21, 2009:371–4hether the device is deactivated is the decision of the patient and
amily. Because patients with ICDs are cared for by physicians of
variety of specialties with differing views, future interventions to
mprove conversations about device deactivation should be targeted
o both specialists and generalists, with the appropriate timing of
hese conversations determined by subsequent empirical studies.
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or this work. This research is supported by Dr. Nathan Goldstein’s Mentored
ontinuedTable 1 Continued
Cardiologists
If a patient is hospitalized frequently, I am/would
be more inclined to discuss deactivation with
him/her.
Agree 11 (37)
Neutral/disagree 19 (63)
If a patient has worsening organ function, I am/
would be more inclined to discuss
deactivation with him/her.
Agree 25 (83)
Neutral/disagree 5 (17)
alues are n (%). Clinicians were asked to rate these statements on a scale of 1 to 5, where 1 was “
n reporting these data, the investigators report the Likert scales as strongly agree or agree (noted
here was no mention about an implantable cardioverter-defibrillator (ICD) in a particular statem
omparisons across the 4 groups of clinicians. All results were obtained using the chi-square test,
n asterisk (*) next to the p value.atient-Oriented Research Career Development Award (1K23AG025933). Dr. d
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ardiac Intensive Care Unit
oised for Real Time?
trict glucose control has been promoted in many intensive care
nit (ICU) settings, including the cardiac ICU, because of the
otion that this will “lower the risk of mortality in critically ill
atients” (1). However, enthusiasm should be tempered by a
ealization that the landmark trial showing benefit is wrought withrom such a strategy. Ceriello et al. (1) assert that “strong evidence
or tight glycemic control as a key strategy for improving prognosis
fter acute coronary syndromes comes from the study by Van den
erghe et al.” (2). However, this study was done on surgical
atients, and the greatest decrease in mortality occurred in patients
ith sepsis. Additionally, concerns have been raised regarding
ncharacteristically high mortality rates in the control group and
or the concomitant use of a high-dose glucose infusion and
arenteral nutrition (3), which is not a standard practice strategy
4). Ceriello et al. (1) also cite beneficial findings of strict glucose
ontrol in the medical ICU (5), without noting that comparisonsEl
strongl
in Tab
ent, tn this trial were made with historical controls, making it difficult
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July 21, 2009:371–4o tease out what, if any, benefit accrued from strict glucose control
s opposed to other changes in ICU management over time.
In contrast, recent studies have demonstrated no mortality
enefit and more adverse outcomes with strict glucose control
6,7). One multicenter, randomized controlled trial conducted in
8 centers using treatment protocols based on the trial by Van den
erghe (2) was stopped early, because there was no significant
ortality difference and the intensive-therapy group experienced
igher rates of severe hypoglycemia than the conventional-therapy
roup (17.0% vs. 4.1%, p  0.001), higher rates of serious adverse
vents (10.9% vs. 5.2%, p 0.01), and a trend to longer ICU stays
6). Another multicenter, randomized controlled study conducted
n 7 countries and in 21 ICUs was halted prematurely, because of
afety concerns and an increased rate of hypoglycemia and a trend
oward higher mortality in the intensive-therapy group (7). In
nother cohort study of 10,456 ICU patients, there was also a
rend toward higher mortality with strict glucose control (8).
inally, a meta-analysis of 29 randomized controlled trials of 8,432
CU patients demonstrated no hospital mortality benefit of strict
lucose control and no significant difference in mortality when
tratified by glucose goal, but there was a 5-fold increased risk of
ypoglycemia, leading the authors to conclude, “tight glucose
ontrol is not associated with significantly reduced hospital mor-
ality but is associated with an increased risk of hypoglycemia” (3).
aken together, one is left to question the purported “beneficial”
ffects of strict glucose control in the ICU setting over the
otential for significant harm incurred by hypoglycemia.
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eply
thank Drs. Kapoor and Kapoor for their letter concerning our
ecent paper (1). They question the evidence that a strict glycemic
ontrol might be beneficial in cardiac intensive care unit.First of all, I would like to underline that the available evidence
as been considered strong enough to induce the American Heart
ssociation to suggest controlling hyperglycemia during acute
oronary syndrome (2).
Furthermore, certainly the letter has been written before the
ublication from Kosiborod et al. (3), who definitively show—
ollowing 7,820 patients—that glucose normalization after admis-
ion is associated with better survival in hyperglycemic patients
ospitalized with acute myocardial infarction whether or not they
eceive insulin therapy.
My worry is that we are still debating about the usefulness of
owering glucose, although evidence is forthcoming suggesting
hat this might not be enough, because the “variability of glucose”
s also probably involved in worsening the prognosis of patients in
he critical care setting (4,5).
The hypothesis that maintaining the level of glycemia under
ery strict control would be relevant in any clinical setting is, in my
pinion, stressed by the recent evidence that in normal people
lycemia is always maintained in a very narrow range of 70 to 140
g/dl (6). One can argue that, if the human body spends so much
nergy to maintain the blood glucose level under so strict a range,
t is because otherwise it could be deleterious. So, in my opinion—
hile waiting for more detailed, ad hoc designed studies, particu-
arly intervention studies—it is already the time for a step ahead
nd to raise attention to this new therapeutic challenge not only for
iabetes but also for a number of critical conditions.
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